Recent

% | $
Quotes you view appear here for quick access.

IsoRay, Inc. Message Board

  • goodbrain007 goodbrain007 Jun 17, 2014 1:06 PM Flag

    cs 131 lung trials.......double news coming?

    NCT01237171....
    Primary Outcome Measures:
    •Local Recurrence [ Time Frame: 3 Years ] [ Designated as safety issue: No ]
    Cancer regrowth in the area where it was surgically removed
    Secondary Outcome Measures:
    •Quality of Life [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Using questionnaires, data will be collected related to the sense of well-being experienced by the patient after treatment.
    Estimated Enrollment: 40
    Study Start Date: November 2010
    Estimated Study Completion Date: May 2014
    Estimated Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
    ****
    NCT01757158
    Primary Outcome Measures:
    •Efficacy [ Time Frame: 5 years ] [ Designated as safety issue: No ]
    To assess local recurrence rate after a wedge resection and Cs-131 implant.
    Secondary Outcome Measures:
    •Quality of Life [ Time Frame: pre-surgery, 3 months, 12 months, 24 months ] [ Designated as safety issue: No ]
    To assess quality of life (as related to side effects) of Cs-131 seed placement after limited surgical resection in lung cancers and compare it to already existing data on I-125 tolerability.
    Estimated Enrollment: 40
    Study Start Date: February 2012
    Estimated Study Completion Date: June 2018
    Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
    ***
    JMHO

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Are you prepared?.....it's here.:)jmho

      Sentiment: Strong Buy

    • or triple news?? lol......JMHO

      Sentiment: Strong Buy

    • bashers.....call the number at the bottom and talk to the good doctor? if you dare.
      ********
      Impact on Patient Care
      According to Dr. Robert Sinha, director of Radiation Oncology for El Camino Hospital, "The launch of mesh brachytherapy treatment further enhances our hospital's ability to treat all lung cancer patients, regardless of their stage. Brachytherapy is a terrific tool that complements our existing services, which include all advanced forms of radiation therapy, such as the CyberKnife system. When it comes to state-of-the-art lung-cancer treatment, we now have all surgical, chemotherapy and target radiation options available for our patients."

      Adds Dr. Khuntia, "Mesh brachytherapy can dramatically reduce the recurrence rate for early-stage lung-cancer patients. In John's case, with surgery alone, there would have been about a 20 percent chance that his cancer would come back locally. With brachytherapy, recurrence is just one percent. That's a significant difference."

      By choosing brachytherapy treatment, John was also able to return home a day after his surgery and will be able to avoid the five-to-six-week process of daily treatments, as would have been required with conventional radiation therapy.

      Brachytherapy treatment is only available to early-stage lung-cancer patients who meet the current treatment guidelines. To find out more about the treatment, contact the El Camino Hospital Center for Advanced Radiotherapy and CyberKnife Radiosurgery at 650-940-7280.
      ******
      JMHO

      Sentiment: Strong Buy

    • Study completion date JUNE 2018…all i needed to know!

    • :) JMHO

      Sentiment: Strong Buy

 
ISR
1.6701+0.0101(+0.61%)9:45 AMEDT